ABSTRACT
The pharmacokinetic rationale for intraperitoneal (IP) drug delivery is well characterized in terms of drug concentrations and their ratio in various bodily compartments. Depending on the physicochemical properties of the drug, the resulting ratio of peritoneal fluid/plasma area under the concentration over time curve (AUC) allows to deliver a high(er) IP dose while plasma exposure, and its associated toxicity, remains limited.
